Original news and analysis on international IP policy
During a visit to France last week, Fadi Chehadé, the CEO and president of the Internet Corporation for Assigned Names and Numbers (ICANN), announced that his Board of Directors has given him the green light to further explore reforms of ICANN. Among them is the possibility of creating a parallel ICANN international structure, likely based in Geneva.
World Trade Organization members at the WTO intellectual property committee this week held fast to positions on longstanding issues, but engaged in discussions on issues such as innovation in relation to universities, and so-called “non-violation complaints” against countries that may cause harm to another country but don’t violate a WTO rule. Also discussed was the ongoing dispute over plain packaging requirements for tobacco products.
The United States House of Representatives Committee on Oversight and Government Reform today released a report detailing the US Food and Drug Administration's "highly-invasive" surveillance programme that monitored employees who contacted Congress and the media, according to a press release from the committee leaders. Surveillance was unauthorised and whistleblowers were not given sufficient protection, the report found.
UNITAID is expected to soon publish a report on the implications of the leaked provisions of the Trans-Pacific Partnership agreement (TPP) on public health and access to medicines.
It began last May, when a tiny state in the United States launched a novel legal attack against a notorious patent troll. Other states and the federal government soon followed, all asserting that the troll’s efforts to licence its patents violated consumer protection laws. At first, this new legal strategy produced some significant victories. Many experts and government officials embraced consumer protection law as an important new tool against patent trolls. But a recent court ruling has cast doubt on the future of this once-promising strategy.
Efforts to update European Union trademark law have slowed amid political differences and squabbles over some provisions of the reform package, representatives from the European Commission (EC), European Parliament and trademark community say. Contrary to the wishes of the EC and lawmakers, the legislation will not be completed before European parliamentary elections in May.
The intersection of biotechnology and intellectual property continues to be a hot topic across the globe. From the patenting of certain plant varieties to human genes, to biodiversity and food security, to genetic resources, countries from developing to developed are attempting to navigate often blurred lines in terms of what can and cannot be patented, what should - and shouldn’t - be patented, and protecting innovators from farmers to plant breeders to drug manufacturers.
The United States, home to the organisation that oversees technical aspects of the internet domain name system, has advice for an upcoming meeting in Brazil aimed at revisiting the global internet governance: consider principles developed in past meetings, and don't retread old sore spots. In other words, don't disrupt the status quo.
Mike Palmedo at Infojustice.org writes: "The U.S. International Trade Commission (ITC) is currently investigating “Indian industrial policies that discriminate against U.S. imports… and the effect those barriers have on the U.S. economy and U.S. jobs.” The investigation was requested by Sen. Hatch, Sen. Baucus, Rep. Camp, and Rep. Levin, and the final report is due to be released in November. Last week it held a series of hearings, where it heard from U.S. business, Indian business, and civil society representatives."
There have been several important developments related to copyright in the European Union in the past week. Below is a summary.
The White House today announced measures that it said will advance its battle against "patent trolls", and urged Congress to pass patent reform legislation toward the effort. And the United States Patent and Trademark Office (USPTO) issued a statement on its work in support of the executive actions.
Nazeem Mohamed is chief executive officer of Kampala Pharmaceutical Industries (KPI), a Ugandan generic manufacturer. Local manufacture of medicines is described by many, including the World Health Organization, as one of the tools that will increase access to medicines. Mohamed is former vice-president of strategic product development at Novo Nordisk, based in Belgium. He also worked for several leading multinational companies such as Pfizer and GlaxoSmithKline before his appointment as CEO of KPI.
With Intellectual Property Watch, Mohamed discussed KPI, the challenges of local drug production, the burden of non-communicable diseases, the issue of substandard medicines, rules engineered in the West which can hinder affordability and access in a least-developed country, unfair competition, and unmet skills building needs.